ImmuPharma (LON:IMM) Stock Price Down 10% – Should You Sell?

ImmuPharma plc (LON:IMM)’s stock price dropped 10% during mid-day trading on Monday . The stock traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.25 ($0.15). Approximately 11,107,625 shares changed hands during mid-day trading, an increase of 30% from the average daily volume of 8,513,286 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Stock Down 9.4%

The company has a market cap of £50.02 million, a P/E ratio of -1,124.72 and a beta of 1.53. The firm has a 50 day moving average of GBX 4.46 and a 200-day moving average of GBX 3.33.

ImmuPharma (LON:IMM) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, research analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.